Question 1

What is IGF-1, and what does it do?

Accepted Answer

IGF-1, or insulin-like growth factor 1, is a hormone the body produces every day, mostly in the liver. A 2009 review sets out the chain of command. Growth hormone exercises its growth effects by stimulating insulin-like growth factor I (IGF-I) synthesis in the liver, and by prompting cartilage cells to divide. Growth hormone gives the order and IGF-1 carries much of it out. A 2015 clinical review calls these hormones polypeptides structurally similar to insulin and with broad physiological activity. It adds a caveat worth keeping in view: despite considerable current knowledge of IGF-I, its bioactivity is incompletely understood. Almost none of it travels alone. In the human body, IGF-I circulates in the blood bound to a binding protein-3 (IGFBP-3), which regulates the delivery of IGF-I to target tissues, and particular proteases clip them apart in response to stresses. That matters once anyone injects the hormone, because the same amount behaves differently in two different people.

Question 2

Is the IGF-1 in a blood test the same as the IGF-1 in a vial?

Accepted Answer

Chemically it is the identical molecule. Everything else about the two situations differs, and that is where demand for this compound quietly separates into halves. One group of readers is interpreting a number on a laboratory report: their own circulating IGF-1, and what moves it. That number measures the body's own production. A 2015 review places measurement of IGF-I at the centre of the diagnosis and treatment of, for example acromegaly and growth hormone deficiency, which is the purpose the assay was developed for. The other group is holding a vial, and administering IGF-1 from outside is a different act with a separate history. A 2022 investigation of more than 400 research participants identified depletion of IGF1 as the biological signature most strongly associated with neurodegeneration in Down syndrome. That is a finding about a circulating level, not about an injection. Those are different questions, and only the first has been investigated at scale.

Question 3

What is IGF-1 LR3?

Accepted Answer

IGF-1 LR3, written out as Long R3 IGF-1, is a modified version of the hormone, and it is the form most often sold as a research compound. A 2026 review lists it among the IGF-1 analogues, alongside pegylated mechano growth factor, that appear in self-administration protocols online. The change exists to make the molecule last longer in the blood. It is made in a vat rather than taken from a body. A 2023 paper reports that human IGF-1 and its analog Long R3 IGF-1 (LR3 IGF-1) are recombinant expressed and produced in the Pichia pastoris expression system, a yeast used widely for making proteins. The purified material matched standard IGF-1 at driving cells to divide. Two consequences follow, pointing opposite ways. The molecule is genuine, and a laboratory can manufacture it to a serious standard. A laboratory yield settles nothing about the contents of a vial purchased elsewhere, because no analysis among the research behind this page has characterised that material.

Question 4

Has IGF-1 ever been given to people?

Accepted Answer

Yes, and over a longer span than almost any compound on this site. A 2009 review records that injectable recombinant human IGF-I, sold as mecasermin, has been available for nearly 20 years. Its licensed use covers the rare instances of GH insensitivity caused by GH receptor defects or GH-inhibiting antibodies. Two decades of availability is a genuine record, and it belongs to one small population of children. Beyond growth failure, the hormone has been given in Rett syndrome, a disorder of brain development caused by a fault in the MECP2 gene. A 2022 analysis sets out what happened. A 20-week open-label phase I trial in children showed significant improvements in breathing. The randomised phase II trial that followed did not show significant improvements in primary outcomes, though two secondary endpoints moved. Nine participants were analysed in the phase I work. A 2025 systematic review of the same literature ends in the same place, calling for larger and better designed trials.

Question 5

What is IGF-1 approved for?

Accepted Answer

One rare condition, in children, and nothing past it. Mecasermin is approved in the US for long-term use in growth failure in children with severe primary IGF-I deficiency, or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. The EU approval covers growth failure in children and adolescents with severe primary IGF-I deficiency. A second preparation, mecasermin rinfabate, pairs the hormone with its binding protein and was cleared by the US Food and Drug Administration on the same narrow grounds. What no regulator has approved is any IGF-1 preparation for muscle, physique or sport. The 2026 review states that absence alongside the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. A Canadian funding review shows how tightly the approved use is drawn. Cover was advised only for patients at least 2 years of age with a confirmed diagnosis and in whom epiphyseal growth plates have not yet closed, meaning whose bones can still lengthen, and only on a children's hormone specialist's prescription, never alongside growth hormone.

Question 6

Will IGF-1 make me bigger?

Accepted Answer

In children who cannot produce enough of it, yes, and the figures are specific. In a non-comparative multicentre trial of 76 children with growth failure and severe IGF-1 deficiency, mean height velocity increased from 2.8 cm/year at baseline to 8.0 cm/year during the first year, and mean growth velocities remained above baseline for up to 8 years. In a separate group monitored across four to five years, 80% of subjects achieved at least a proper rate of growth compared to a healthy group. Consider what those investigations measured. Height, in children whose epiphyseal growth plates remain open, meaning the cartilage at the ends of a growing bone, who began with a diagnosed deficiency. The same 2009 review supplies the ceiling from inside the clinic: full restoration of normal growth, as occurs with rhGH replacement of GH deficiency, is not seen. Muscular size in an adult already producing a normal concentration is a different question, and no trial among the research behind this page has measured it. That is an absence of investigation rather than a null result.

Question 7

Does IGF-1 LR3 make you stronger?

Accepted Answer

No study among the research behind this page has administered IGF-1 LR3 to a person and measured strength. What exists is animal and cellular work, and the most detailed of it concerns cardiac muscle in fetal sheep rather than skeletal muscle in an adult. That work repays a careful reading, because it contradicts the usual assumption. In vivo administration of Long R3 IGF-1 (LR3 IGF-1) did not stimulate cardiomyocyte hypertrophy but led to a decreased percentage of cells that were binucleated in vivo. In culture, LR3 IGF-1 increased myocyte bromodeoxyuridine uptake by three- to five-fold, an in vitro indication of cells dividing. The authors conclude that IGF-1 through IGF1R does not stimulate hypertrophy either in vivo or in vitro. Hypertrophy means cells enlarging, which is what somebody training for size is pursuing. In that animal the hormone generated cell division instead. Those are different questions concerning different tissue in a different species.

Question 8

What is a normal IGF-1 level by age?

Accepted Answer

No universal figure appears in the research supporting this page. Reference ranges for IGF-1 are generated by the laboratory performing the assay, and they vary with age and with methodology, so a result is interpreted against age-matched peers rather than against a fixed number. What the clinical literature supplies instead is how the measurement is used. A 2015 review places measurement of IGF-I at the centre of the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The threshold for the one approved use is on record too, written as a score rather than a raw value. Severe primary IGF-1 deficiency means a basal IGF-1 standard deviation score (SDS) at or below -3, with a height SDS at or below -3, in a child whose growth hormone is normal or high. A standard deviation score describes a position relative to others of the same age, so the comparison carrying meaning is against age-matched peers.

Question 9

What happens if IGF-1 is too high?

Accepted Answer

A persistently high IGF-1 in an adult is the marker of acromegaly, a condition driven by excessive growth hormone. A 1994 review in Drugs traces it to a pituitary adenoma, meaning a benign tumour of the pituitary gland, in the majority of cases. It is frequently diagnosed years late, and it causes serious damage to cardiac, pulmonary and musculoskeletal tissue. That same review calls a raised plasma IGF-I the single best test to make the diagnosis. The marker then shows whether management is working, since GH secretion is best assessed by determining whether plasma IGF-I returns to the normal range. A second concern belongs to prolonged exposure rather than to any individual reading. A 2009 review states that the anti-apoptotic properties of IGF-I are implicated in cancer pathogenesis, a concern for long-term therapy. Anti-apoptotic means cells become less inclined to die on schedule. No study we could find has quantified that risk outside supervised clinical use.

Question 10

What increases IGF-1 the most?

Accepted Answer

Growth hormone, by a considerable margin, and the relationship is undisputed. The 2009 review states it directly: growth hormone exercises its growth effects by stimulating insulin-like growth factor I (IGF-I) synthesis in the liver. Whatever elevates growth hormone elevates IGF-1 downstream of it, which is the reasoning behind the growth-hormone peptides marketed alongside this one. Two things often said to move the number — vitamin D and dietary sugar — are not measured against IGF-1 anywhere in the research supporting this page. That is an absence of investigation rather than a finding of no effect, and the two descriptions are not the same. What is documented runs the other way, and it concerns a disease rather than a habit. Across more than 400 research participants, individuals with trisomy 21 displayed chronic IGF1 deficiency downstream of growth hormone production, tied to a raised inflammatory marker. Shorter children in that group showed a deeper deficiency. So the level tracks illness, which is a different matter from a lever anybody can pull.

Question 11

How do you reduce IGF-1 levels?

Accepted Answer

The only route documented here is to deal with whatever is pushing the level up, which in practice means acromegaly. The 1994 review sets out the order. Surgical resection of the tumour is almost always the first step, and if growth hormone output is not brought back to normal, radiation or drug therapy follows. Two medicines appear in that account with numbers attached. Bromocriptine normalises GH in approximately 10% of patients and causes pituitary shrinkage in a similar fraction of patients. Octreotide is considerably more expensive than bromocriptine and is given subcutaneously, but is more effective in both normalising GH secretion and in shrinking tumours. That is a clinical pathway for a diagnosed disease, recorded as a fact rather than as something to act on. Nothing in the research supporting this page measures diet, fasting, exercise or any supplement against a person's IGF-1. The popular answers to this question therefore rest on something other than the evidence above.

Question 12

Does IGF-1 affect testosterone?

Accepted Answer

No study among the research behind this page supporting this page measures testosterone in anybody given IGF-1. That is a flat gap, and dressing it up with a mechanism story would be worse than leaving it open. The nearest signal concerns early puberty rather than testosterone itself. In an analysis of 529 reports of drug-induced early puberty sent to the FDA adverse event reporting system between 2004 and 2024, the drugs with the highest reporting odds ratios included mitotane at 220.35, mecasermin at 145.42 and clomifene at 141.35. A reporting odds ratio measures disproportion: a pairing turning up more often than chance in a voluntary system, not a medicine causing the event. Early puberty involves the sex hormones, so that signal is not beside the point. It comes from reports about children given an approved medicine for a growth disorder, and a report is not a measurement. Whether an adult's testosterone responds to IGF-1 is a different question, and no study among the research behind this page has published an answer.

Question 13

What are the downsides of taking IGF-1?

Accepted Answer

Nearly all the documented harm comes from supervised use in children, and it is specific enough to be worth knowing. A 2009 review names low blood sugar as the most frequent side effect, readily controlled by taking the dose with meals. It also lists swelling of lymph tissue, which may need surgery on the tonsils, a build-up of body fat, and a coarsening of the face. Low blood sugar is the one that recurs. A 2007 review notes adverse events, particularly hypoglycemia, reported with administration of unbound recombinant human IGF-I, which is why the binding-protein preparation was developed. For the analogues sold online the picture is broader and considerably weaker. The 2026 review reports endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms and injection-site reactions across the whole class. What is documented, who was excluded from these investigations and what remains unmeasured are set out on the safety page.

Question 14

How is IGF-1 thought to work?

Accepted Answer

IGF-1 binds its own receptor on the surface of a cell and activates two signalling routes. The fetal sheep work names them: IGF-1 stimulates the IGF-1 receptor (IGF1R) and downstream signaling pathways, including extracellular signal-regulated kinase (ERK) and phosphoinositol-3 kinase (PI3K). Both are chains of molecular switches determining whether a cell divides or matures. Blocking either chain eliminated the division signal in that animal experiment, so both appear necessary rather than merely present. Away from cardiac tissue, the hormone is described as neurotrophic, meaning supportive of nerve cells. A 2016 review calls IGF-1 a neurotrophic polypeptide with crucial roles to play in Central Nervous System (CNS) growth, development and maturation, which is the reasoning that produced the Rett syndrome and Fragile X investigations. The plain version is short. IGF-1 is the message growth hormone sends to tissue, and tissue interprets it as an instruction to divide, mature or absorb glucose. What that message accomplishes in an adult already receiving it normally is the part no study among the research behind this page has measured.

IGF-1